Episodic Memory

Uses

How it works

Dosage & preparation

Highlighted claims

• The primary outcome is improvement in the PROMEA visual object learning test, assessed after 3 months of treatment. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
• A 22% increase in mean PROMEA total score at 3 months is defined as a clinically significant treatment response. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
• Long-term visual episodic memory is a hippocampus-dependent function that is commonly impaired in Down syndrome. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
• Secondary memory outcomes include visual-spatial learning, verbal learning, associative memory, and a parent-completed observer memory questionnaire. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
• The processing dissociation procedure is designed for people with intellectual disability and estimates the separate contributions of recollection and familiarity. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial